Arcturus Therapeutics Holdings (ARCT) EBT (2018 - 2026)

Arcturus Therapeutics Holdings (ARCT) has 9 years of EBT data on file, last reported at -$56.6 million in Q1 2026.

• Quarterly EBT fell 302.2% year-over-year to -$56.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$108.3 million (down 57.97% YoY) and the FY2025 annual result came in at -$65.8 million, up 18.73% from the prior year.
• EBT fell to -$56.6 million in Q1 2026, from -$29.1 million in the prior quarter.
• In the past five years, EBT ranged from a high of $118.6 million in Q4 2022 to a low of -$56.6 million in Q1 2026.
• A 5-year average of -$13.0 million and a median of -$17.4 million in 2024 frame the typical range for EBT.
• Annual changes were most pronounced in 2022 — EBT soared 413.74% — and 2026, when it slumped 302.2%.
• Tracing ARCT's EBT over 5 years: stood at $118.6 million in 2022, then tumbled by 109.65% to -$11.4 million in 2023, then sank by 162.2% to -$30.0 million in 2024, then grew by 3.09% to -$29.1 million in 2025, then plunged by 94.66% to -$56.6 million in 2026.
• The last three EBT figures came in at -$56.6 million (Q1 2026), -$29.1 million (Q4 2025), and -$13.4 million (Q3 2025), per Business Quant data.